| 제품명 | Empagliflozin |
|---|---|
| CAS 번호 | 864070-44-0 |
| 분자식 | C23H27ClO7 |
| 분자량 | 450.91 |
| 외관 | 흰색에서 미백색의 결정성 분말 |
| 분석법 (HPLC) | ≥98% |
| 건조 손실 | ≤0.5% |
| 소각 잔류물 | ≤0.1% |
| 중금속 | ≤10 ppm |
| 융점 | 152-156°C |
| 특정 회전 | -10° to -15° (c=1, methanol) |
도움이 필요하신가요? 저희 팀에 문의해 주세요

동의어
Empagliflozin, Jardiance, BI-10773, 1-Chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene
Empagliflozin has quietly become one of the most prescribed SGLT2 inhibitors in the world, and it’s not hard to see why. Unlike older diabetes drugs that just push insulin harder, empagliflozin works by telling the kidneys to let go of excess glucose — literally flushing it out through urine. That mechanism not only lowers blood sugar but also delivers a nice side effect: many patients see modest weight loss and a reduction in cardiovascular risk. For a diabetic patient, that’s a triple win.
For manufacturers, empagliflozin is a workhorse API. It’s the active ingredient in Jardiance, which has been shown to reduce cardiovascular death in type 2 diabetes patients — a claim not many oral antidiabetics can make. We supply empagliflozin as a high-purity crystalline powder, with every batch tested to meet strict spec limits. Whether you need 1 kg for R&D or a full drum for production, we’ve got you covered, and our lead times are short enough to keep your line moving.